Skip to main content

Table 3 Frequency of healthcare resource use

From: Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective

 

BRVO

CRVO

 

Ranibizumab

Laser Photocoagulation

Ranibizumab

Observation

Treatment visits

  First Year

7.0

1.4

8.2

0

  Second Year

2.1

0.3

3.5

0

Follow-up visits

  First Year

2.3

4.9

2

5.4

  Second Year

0.8

1.8

1.4

3

  Third Year

1.1

1

0.8

1.3

  Fourth Year

0.6

0.8

0.3

0.8

  Fifth Year

0.2

0.2

0.3

0.3